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ABSTRACT
We aimed to evaluate the efficacy of dual inhibition of epidermal growth factor 
receptor (EGFR) with nimotuzumab (EGFR monoclonal antibody) plus gefitinib 
(EGFR-tyrosine kinase inhibitor) in advanced non-small cell lung cancer (NSCLC) 
after platinum-based chemotherapy. An open label, randomized, phase II trial was 
conducted at 6 centers; 160 patients were randomized (1:1) to either gefitinib 
alone or nimotuzumab (200 mg, i.v. weekly) plus gefitinib (250 mg p.o. daily) until 
disease progression or intolerable toxicity. The primary endpoint was progression-
free survival (PFS) at 3 months. Of the total 160 enrolled patients, 155 (77: gefitinib, 
78: nimotuzumab plus gefitinib) received at least one dose and could be evaluated 
for efficacy and toxicity. The majority had adenocarcinoma (65.2%) and ECOG 
performance status of 0 to 1 (83.5%). The median follow-up was 22.1 months, and 
the PFS rate at 3 months was 48.1% in gefitinib and 37.2% in nimotuzumab plus 
gefitinib (P = not significant, NS). The median PFS and OS were 2.8 and 13.2 months in 
gefitinib and 2.0 and 14.0 months in nimotuzumab plus gefitinib. Combined treatment 
was not associated with superior PFS to gefitinib alone in patients with EGFR mutation 
(13.5 vs. 10.2 months in gefitinib alone, P=NS) or those with wild-type EGFR (0.9 
vs. 2.0 months in gefitinib alone, P=NS). Combined treatment did not increase EGFR 
inhibition-related adverse events with manageable toxicities. The dual inhibition of 
EGFR with nimotuzumab plus gefitinib was not associated with better outcomes than 




Lung cancer is the second most common cancer type 
and the leading cause of cancer death worldwide [1, 2]. 
Non-small cell lung cancer (NSCLC) is approximately 
85% of lung malignancies and most patients are diagnosed 
with far advanced stage NSCLC. Although agents that 
target specific genetic alterations have been developed for 
lung cancer treatment, the prognosis of lung cancer is still 
poor and the 5-year survival rate has been less than 5% in 
advanced-stage disease. 
The epidermal growth factor receptor (EGFR) is 
overexpressed on various types of solid cancers, including 
NSCLC [3]. Although the prognostic or predictive 
function of EGFR expression in patients with NSCLC 
remains controversial, some researches have suggested 
that upregulation of EGFR expression is related to tumor 
establishment and spread and poor prognosis in NSCLC 
[3-5]. Dysregulation of EGFR in several tumors including 
lung cancer, head and neck cancer, esophageal cancer, 
and others, correlated with metastasis and poor survival 
outcome[5]. Increased knowledge of EGFR signaling 
pathway regulation in NSCLC has led to develop targeted 
agents. Anti-EGFR monoclonal antibodies which bind 
to the extracellular domain of this receptor, or small-
molecule tyrosine kinase inhibitors which block the kinase 
domain are currently available EGFR-targeted drugs [3, 
6, 7]. These EGFR-targeted agents have been related with 
improvement in survival of NSCLC patients. Recently, 
the SQUIRE, FLEX, and INSPIRE trials showed that 
the combination of EGFR monoclonal antibodies, such 
as necitumumab and cetuximab, with platinum-based 
cytotoxic chemotherapy as a first-line therapy in squamous 
cell lung cancer led to prolonged survival outcomes, while 
the same results were not seen in adenocarcinoma [8-11]. 
However, the role of anti-EGFR antibodies in NSCLC has 
not been established.
Nimotuzumab (TheraCIM®) is a humanized IgG1 
mAb targeting EGFR [3]. Nimotuzumab adheres to the 
extracellular domain III of EGFR with moderate affinity, 
blocking EGF ligand binding and receptor dimerization 
by steric hindrance [3]. Nimotuzumab demonstrated 
inhibitory activity on tumor cell growth, angiogenesis, 
and apoptosis [5, 12]. Phase I and II clinical trials with 
nimotuzumab presented the lack of a severe dermatologic 
reaction unlike other anti-EGFR drugs [3, 13]. In previous 
trials that focused primarily on brain malignancies or 
head and neck cancer, nimotuzumab has demonstrated 
greater efficacy similar to other anti-EGFR mAbs [3, 14-
17]. Two recent phase I clinical trials in NSCLC patients 
demonstrated the minimal toxicity of nimotuzumab 
combined with radiation therapy and also presented 
favorable antitumor effects [3, 18, 19].
Activating mutations of the EGFR gene, mainly 
exon 19 deletions and exon 21 a single missense 
mutation, were known to correlate with clinical 
response to gefitinib [3]. Gefitinib significantly improve 
progression-free survival (PFS) in NSCLC patients who 
had activating EGFR mutations. Three phase III clinical 
trials conducted exclusively in EGFR mutated patients [6, 
7, 20] demonstrated that patients with EGFR mutations 
experienced longer PFS with gefitinib treatment than 
cytotoxic chemotherapy. These large-scale trials suggested 
that EGFR mutation in tumors is a strong predictive 
biomarker of better gefitinib-associated outcomes. 
Many preclinical data support the combination 
of EGFR targeting therapy with EGFR-TKIs and anti-
EGFR mAbs to get over intrinsic or acquired resistance 
mechanisms and to amplify the potency of EGFR 
signaling inhibition[3, 21-23]. These data suggest that 
dual blockade of EGFR pathway could be new treatment 
strategies to maximize effective target inhibition. 
Recent phase I/II trials that added cetuximab to erlotinib 
demonstrated stable disease in majority of patients (11 of 
13) with acquired resistance, although there was no partial 
response on radiologic images. It is to be noted that one 
third of the patients discontinued combined therapy due to 
intolerable rash [3, 24]. Thus, it is important to develop a 
tolerable dual blockade of the EGFR pathway with EGFR 
mAb plus EGFR-TKI and to identify clinical applicability. 
We already performed the phase I clinical trial to 
determine recommended phase II dosing (RPIID) and 
safety of the combination of gefitinib and nimotuzumab 
[3]. This phase I trial demonstrated a well-tolerated safety 
profile without dose-limiting toxicity and 25% partial 
response (4/16 patients) and 43.8% stable disease (7/16 
patients) [3]. Based on these phase I trial results, the 
RPIID for nimotuzumab is a 200 mg weekly i.v. and for 
gefitinib 250 mg daily p.o.[3] We evaluated the efficacy of 
dual inhibition of the EGFR pathway with nimotuzumab 
plus gefitinib in advanced NSCLC patients who were 
previously treated with platinum-based chemotherapy. 
RESULTS
Patient characteristics
A total of 160 patients were enrolled between Feb. 
2012 and Jun. 2014 at 6 centers in Korea. Of 160 patients, 
80 were randomly allocated to the gefitinib and 80 patients 
were assigned to nimotuzumab plus gefitinib. Five patients 
(2 in nimotuzumab plus gefitinib 3 in gefitinib arm) 
withdrew consent before treatment. Finally, 155 patients 
received at least one dose and could be evaluated for 
efficacy and toxicity in this study. Progressive disease 
was confirmed in 139 patients by the data cutoff point of 
March, 30th 2016 (Figure 1).
The median age was 63 years old and 102 patients 
(63.8%) were male. The majority (98.1%) were ECOG 
PS 0 or 1. Fifty-six patients (35.0%) were never/light 
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smokers and 106 patients (66.2%) had adenocarcinoma. 
The stratification factors were well balanced in 
nimotuzumab plus gefitinib and gefitinib groups: 66.2% 
and 66.2% in adenocarcinoma, 13.8% and. 25.0% in 
EGFR mutation, and 31.2% and 38.8% in never smoker. 
Patient characteristics were well assigned in both groups 
and patient baseline characteristics were summarized in 
Table 1.
Of 160 enrolled patients, 115 were available for 
EGFR mutation analysis, mainly because of insufficient 
tissue materials. Among 115 with available results of 
EGFR mutation, EGFR mutation (14 in Exon 19 del 
mutation, 11 in Exon21 L858R mutation, 3 in Exon18 
G719X mutation and 3 in Exon 20 insertion mutation) 
was documented in 31 patients. Eleven of these patients 
were in nimotuzumab plus gefitinib and 20 patients in 
gefitinib alone. Seventy-seven patients were available 
for KRAS mutation results and 7 (4.3%) patients were 
positive (5 patients in nimotuzumab plus gefitinib and 
2 patients in gefitinib). In regards to previous platinum 
Table 1: Baseline patient characteristics
Characteristics Total (n = 160)
Experimental arm
Nimotuzumab+





n (%) n (%) n (%)
Age, years 0.80
Median 63 63 63
Range 31-84 31-84 37-83
Sex 0.41
Male 102 (63.8%) 54 (67.5%) 48 (60.0%)
Female 58 (36.2%) 26 (32.5%) 32 (40.0%)
ECOG performance status 0.13
0 77 (49.7%) 41 (52.6%) 36 (46.8%)
1 75 (48.4%) 34 (43.6%) 41 (53.2%) 
2 3 (1.9%) 3(3.8%) 0 (0%) 
Smoking 0.40
Never/light smoker 56 (35.0%) 25 (31.2%) 31 (38.8%)
Ever smoker 104 (65%) 55 (68.8%) 49 (61.2%)
Histology 0.56
Adenocarcinoma 106 (66.2%) 53 (66.2%) 53 (66.2%)
Non-adenocarcinoma 54 (33.8%) 27 (33.8%) 27 (33.8%)
Brain metastasis 0.65
Yes 30 (18.8%) 16 (20.0%) 14 (17.5%)
EGFR mutation 0.36
Positive 31 (19.4%) 11 (13.8%) 20 (25.0%)
Exon19 del 14 (8.8%) 3 (3.8%) 11 (13.8%)
Exon21 L858R 11 (6.9%) 7 (8.8%) 4 (5.0%)
Other† 6 (3.8%) 1 (1.2%) 5 (6.3%)
Negative 84 (52.5%) 39 (48.8%) 38 (47.5%)
Not evaluable 45 (26.9%) 29 (36.2%) 27 (33.8%)
KRAS mutation 0.59
Positive 7 (4.3%) 5 (6.2%) 2 (2.5%)
Negative 70 (43.8%) 36 (45.0%) 34 (42.5%)
Unknown 83 (51.9%) 39 (48.8%) 44 (55.0%)
Previous first-line therapy 0.68
Platinum + paclitaxel 77 (49.0%) 38 (48.1%) 39 (50.0%)
Platinum + gemcitabine 41 (26.1%) 22 (27.8%) 19 (24.4%)
Platinum + pemetrexed 35 (22.3%) 16 (20.3%) 19 (24.4%)
Other 4 (2.5%) 3 (3.8%) 1 (1.3%) 
Abbreviations: ECOG, Eastern Cooperative Oncology Group; EGFR, epidermal growth factor receptor; †These six patients 
had in three exon 18 mutation (G719X) and three exon20 insertion mutation. 
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based chemotherapy regimen, platinum + paclitaxel was 
performed in 49.0% of patients, platinum + gemcitabine in 
26.1%, and platinum + pemetrexed in 22.3%. 
Clinical outcomes
The median duration of nimotuzumab plus gefitinib 
and gefitinib administration was 1.8 (range, 0.2-31.5 
months) and 2.8 (range, 0.1-22.6 months) months. 
The ORRs were 22.1% in gefitinib arm and 16.7% in 
nimotuzumab plus gefitinib arm, without statistical 
significance (P = 0.35) (Supplementary Figure 1, Table 2). 
With a median follow-up duration of 22.1 months, the PFS 
rate at 3 months was 37.2% in nimotuzumab plus gefitinib 
and 48.1% in gefitinib [HR 0.99; 95% CI, 0.70–1.38; P = 
0.95]. The median PFS and OS were 2.0 months and 14.5 
Table 2: Tumor response according to RECIST
Response Total†(n = 155)
Nimotuzumab+
Gefitinib (n = 78)
Gefitinib
(n = 77) P
n (%) n (%) n (%)
Response  0.27
  CR 0 (0%) 0 (0%) 0 (0%)
  PR 30 (19.4%) 13 (16.7%) 17 (22.1%)
  SD 62 (40.0%) 29 (37.2%) 33 (42.9%)
  PD 57 (36.8%) 31 (39.7%) 26 (33.8%)
Not assessable 6 (3.9%) 5 (6.4%) 1 (1.3%)
Overall response rate*, % 30 (19.4%) 13 (16.7%) 17 (22.1%) 0.35



















†Five patients (2 in the experimental and 3 in the control arm) withdrew from study before treatment, and were excluded 
from analysis.
Tumor responses were assessed with the use of Response Criteria in Solid Tumors (RECIST), version 1.1
§The disease control rate was calculated as complete response plus partial response plus stable disease
Abbrviations: RECIST, Response Evaluation Criteria in Solid Tumors; CR, complete response; PR, partial response; SD, 
stable disease; PD, progressive disease; PFS, progression free survival; OS, overall survival; CI, confidence interval
Figure 1: Trial profile in this study.
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months in nimotuzumab plus gefitinib and 2.8 months and 
13.2 months in gefitinib [HR 0.99; 95% CI, 0.70–1.38; P 
= 0.95 for PFS; HR 0.93, 95% CI 0.63–1.38, P = 0.72 for 
OS] (Figure 2).
As expected, patients who had EGFR mutations 
demonstrated significantly longer survival than those 
with wild-type EGFR or unknown EGFR mutation (8.4 
vs. 1.8 vs. 2.0 months, P < 0.001 for PFS; 23.5 vs. 13.1 
vs. 6.7 months, P = 0.001 for OS) (Figure 3A and 3B). 
Combined treatment of nimotuzumab plus gefitinib was 
not superior in PFS compared to gefitinib alone in patients 
with EGFR mutations (10.3 vs. 7.4 months in gefitinib 
alone, P = 0.42) and patients with wild-type EGFR (1.0 
vs. 2.3 months in gefitinib alone, P = 0.85) (Figure 3 C and 
D). The histology results indicated that median PFS was 
not significantly different between the two treatment arms 
(2.8 vs. 2.9 months in gefitinib alone for adenocarcinoma, 
P = 0.64; 1.2 vs. 2.8 months in gefitinib alone for non-
adenocarcinoma, P = 0.35). Altogether, the dual inhibition 
of EGFR with nimotuzumab plus gefitinib was not 
associated with better outcomes compared with gefitinib 
alone for second-line therapy of advanced NSCLC.[3]
Table 3: Treatment-related adverse events (N = 155)†
Nimotuzumab+Gefitinib (n=78) Gefitinib (n=75) P-value 
Adverse event All grades Grade 1-2 Grade≥3 All grades Grade 1-2 Grade≥3
N (%) N (%)
 Acneiform rash 37(47.4%) 35(44.9%) 2 (2.6%) 34(44.2%) 33(42.9%) 1 (1.3%) 0.40
 Diarrhea 28 (35.9%) 26 (33.3%) 2 (2.6%) 27 (35.1%) 26 (33.8%) 1 (1.3%) 0.52
 Anorexia 27 (34.6%) 25 (32.1%) 2 (2.6%) 21 (27.3%) 18 (23.4%) 3 (3.9%) 0.28
 Stomatitis 18 (23.1%) 18 (23.1%) 0 (0%) 20 (26.0%) 20 (26.0%) 0 (0%) 0.40
 Dry skin 16 (20.5%) 16 (20.5%) 0 (0%) 16 (20.5%) 16 (20.5%) 0 (0%) 0.40
 Pruritus 16 (20.5%) 16 (20.5%) 0 (0%) 16 (20.8%) 16 (20.8%) 0 (0%) 0.56
Paronychia 12 (15.4%) 12 (15.4%) 0 (0%) 13 (16.9%) 13 (16.9%) 0 (0%) 0.48
AST elevation 11(14.1%) 9 (11.5%) 2 (2.6%) 8 (10.4%) 6 (7.8%) 2 (2.6%) 0.32
ALT elevation 10 (12.8%) 8 (10.3%) 2 (2.6%) 8 (10.4%) 5 (6.5%) 3 (3.9%) 0.29
Myalgia 9 (11.6%) 9 (11.6%) 0 (0%) 7 (9.1%) 7 (9.1%) 0 (0%) 0.60
Nausea 8 (10.3%) 8 (10.3%) 0 (0%) 10 (13.0%) 8 (10.4%) 2 (2.6%) 0.39
Vomiting 5 (6.4%) 5 (6.4%) 0 (0%) 4 (5.2%) 4 (5.2%) 0 (0%) 0.50
Thrombocytopenia 5 (6.4%) 5 (6.4%) 1 (1.3%) 3 (3.9%) 3 (3.9%) 0 (0%) 0.56
Neutropenia 4 (5.1%) 4 (5.1%) 0 (0%) 2 (3.9%) 2 (3.9%) 0 (0%) 0.50
Anemia 3 (3.8%) 3 (3.8%) 0 (0%) 4(5.2%) 4(5.2%) 0 (0%) 0.49
Pneumonitis 3 (3.8%) 3 (3.8%) 0 (0%) 3 (3.9%) 2 (2.6%) 1 (1.3%) 0.65
Toxic-effect grades are based on the National Cancer Institute Common Terminology Criteria (version 3.0).
Figure 2: Kaplan-Meier estimates of A. progression-free survival (PFS) and B. overall survival (OS) of patients with advanced non-
small cell lung cancer that were treated. The differences in median PFS (HR 1.03, 95% CI 0.71-1.41, P = 0.98) and OS (HR 0.86, 95% CI 
0.57–1.30) were not statistically significant between the nimotuzumab plus gefitinib and the gefitinib arm.
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Safety
All patients who had received at least one dose of a 
study drug were analyzed in the safety analysis. Adverse 
events (AEs) in both treatment arms were mostly grade 1 
to 2 and easily manageable. Importantly, combined EGFR 
inhibition with nimotuzumab and gefitinib did not increase 
EGFR inhibition-related AEs, such as acneiform rash 
(47.4% vs. 44.9% in gefitinib alone, P = 0.40), diarrhea 
(35.9 vs. 35.1% in gefitinib alone, P = 0.52), and stomatitis 
(23.1 vs. 26.0% in gefitinib alone, P = 0.40) (Table 3). 
Treatment-related death was not occurred in current trial.
DISCUSSION
This is the first randomized phase II clinical trial 
that assessed combination therapy of nimotuzumab plus 
gefitinib compared to gefitinib in advanced NSCLC 
patients who failed to platinum-based chemotherapy. 
This study presented the feasibility and tolerability of 
combination therapy with nimotuzumab and gefitinib in 
advanced lung cancer patients. However, this randomized 
phase II clinical trial did not prove its primary endpoint, as 
the PFS rate at 3 months was 37.2% in the nimotuzumab 
plus gefitinib compared to 48.1% in the gefitinib alone. 
Moreover, in both patients with and without EGFR 
mutation, combined nimotuzumab plus gefitinib did 
not demonstrate favorable PFS outcomes compared to 
gefitinib alone. Collectively, this study demonstrated 
that the dual inhibition of EGFR with nimotuzumab plus 
gefitinib was not superior to gefitinib alone as second-
line treatment of advanced NSCLC patients. Combined 
therapy with nimotuzumab plus gefitinib showed a 
Figure 3: Kaplan-Meier estimates of A. progression-free survival (PFS) and B. overall survival (OS) of all patients according to 
EGFR mutation status. Patients with EGFR mutations showed significantly longer survival than those with wild-type EGFR or unknown 
EGFR mutation statuses (8.4 vs. 1.8 vs. 2.0 months, P < 0.001 for PFS; 23.5 vs. 13.1 vs. 6.7 months, P =  0.001 for OS). Nimotuzumab 
plus gefitinib was not found to have superior PFS compared with gefitinib monotherapy C. in patients with EGFR mutations (10.3 vs. 7.4 
months in gefitinib alone, P = 0.42) or D. wild type EGFR patients (1.0 vs. 2.3 months in gefitinib alone, P = 0.85).
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manageable toxicity profile, with rash and diarrhea as the 
most frequent treatment-related AEs. The safety profile 
for the combination of nimotuzumab and gefitinib was 
comparable with that of each individual drug and any 
unexpected toxicities were not developed.
Our hypothesis was that dual blockade of the EGFR 
pathway using a combination of nimotuzumab plus 
gefitinib could improve survival outcomes in advanced 
NSCLC patients. However, dual blockade of EGFR 
pathway did not demonstrate favorable survival benefit 
compared to gefitinib alone regardless of EGFR mutation 
status. Although the numbers of EGFR mutated patients 
in this study were too small to make conclusion, dual 
blockade of the EGFR pathway might not be associated 
with superior treatment outcomes over the monotherapy 
with gefitinib even in EGFR mutated patients as well as 
EGFR wild type.
In contrast to previous studies, in our study, 
treatment with the EGFR monoclonal antibody 
nimotuzumab did not prolong survival in squamous 
cell lung cancer patients. In patients who had acquired 
resistance to EGFR-TKI, dual blockage of EGFR with 
afatinib and cetuximab demonstrated robust clinical 
activity in both those with and without T790M mutations 
[25]. This result implicated that a significant portion of 
tumors in patients with acquired resistance to gefitinib or 
erlotinib still remain dependent on EGFR signaling for 
survival. Therefore, more complete blockade of EGFR is 
an effective strategy that could be worthwhile for further 
study in EGFR mutated patients with acquired resistance. 
There are several potential reasons for the lack of 
variation in outcomes between combined- and mono-
therapy. Firstly, the affinity of nimotuzumab is ~10 times 
lower than those of cetuximab and necitumumab, and 
thus this lower affinity of nimotuzumab might cause the 
negligible blocking effect of the EGFR pathway seen in 
our study [13]. Additionally, the small number of enrolled 
patients, slight imbalance in prognostic factors between 
the two treatment arms favoring the gefitinib arm, and 
lack of patient selection based on EGFR expression could 
have led to the negative findings. The percentage of EGFR 
mutation was quite high in the gefitinib arm; although this 
difference was not statistically significant, it may have had 
an impact on treatment outcomes in this clinical trial. 
With regard to AEs, nimotuzumab did not cause 
severe dermatologic reactions compared to other anti-
EGFR antibodies [9, 24, 25]. Combined EGFR inhibition 
with nimotuzumab and gefitinib also did not increase 
EGFR inhibition-related AEs. Considering this favorable 
toxic profile, nimotuzumab could be a good candidate 
anti-EGFR antibody when combined with other drugs.
Conclusively, the dual inhibition of EGFR pathway 
with nimotuzumab plus gefitinib was not associated with 
better outcomes compared with gefitinib alone for second-
line treatment of advanced NSCLC patients, regardless of 
EGFR mutation status. 
PATIENTS AND METHODS
Study design
An open label, randomized, phase II trial was 
designed to prospectively evaluate the efficacy of dual 
inhibition of EGFR with nimotuzumab plus gefitinib in 
advanced NSCLC patients that were previously treated 
with platinum-based chemotherapy. A total of 160 patients 
were allocated in a 1:1 ratio to either the treatment arm 
(nimotuzumab plus gefitinib) or the control arm (gefitinib 
alone) using the minimization method to balance to center, 
histology (adenocarcinoma vs. non-adenocarcinoma), 
EGFR mutation (EGFR mutation vs. wild type), and 
smoking status (never/light vs. ever smoker). The 
treatment arm consisted of 200 mg of nimotuzumab 
administered via intravenous infusion over 30 min, 
once per week, and gefitinib at a fixed dose of 250 mg 
daily until disease progression or unacceptable toxicity. 
The control arm received gefitinib at a fixed dose of 250 
mg daily. Each treatment cycle was defined as 28 days, 
regardless of omitted doses. Further treatment after disease 
progression was at the physician’s discretion.
The primary endpoint was the evaluation of the 
PFS rate at 3 months. Secondary endpoints included PFS, 
OS, ORR and safety. PFS was assessed from the date of 
randomization to that of disease progression determined 
by CT or MRI using RECIST criteria or death from any 
cause. OS was assessed from the date of randomization 
until death from any cause. Target lesions were assessed 
via an independent central review at baseline (within 4 
weeks of randomization). To assess toxicity, the National 
Cancer Institute Common Toxicity Criteria (version 4.0) 
were used during the study period and follow-up. 
This study was conducted in accordance with the 
Declaration of Helsinki, the International Conference on 
Harmonization Guidelines on Good Clinical Practice. The 
protocol was approved by the Protocol Review Committee 
of the Korean Cancer Study Group and by the Institutional 
Review Board at each participating institute. All patients 
provided written informed consent. Study protocol and 
informed consent forms were approved by institutional 
review boards of each institution. The trial is registered 
on ClinicalTrials.gov (clinicaltrials.gov identifier 
NCT01498562, protocol number: KCSG LU12-01).
Patient eligibility
Trial eligibility required pathologically or 
cytologically confirmed stage IV NSCLC; measurable 
disease by Response Evaluation Criteria in Solid Tumors 
Group (RECIST); prior systemic therapy with platinum-
based chemotherapy; a performance status of 0,1, or 2 
based on Eastern Cooperative Oncology Group criteria; 
Oncotarget15950www.impactjournals.com/oncotarget
age 18 years or older; and adequate bone marrow, liver, 
and kidney function. Patients with central nervous system 
metastases were eligible if there were no symptoms 
or treatment for brain metastasis had been completed. 
Patients with prior malignancies were eligible if there was 
no evidence for recurrence for at least 5 years. 
Response evaluation
We performed computed tomography or magnetic 
resonance imaging scans firstly after 4 weeks, and then 
every 8 weeks, or at the time when disease progression 
was suspected. Based on the Response Evaluation Criteria 
in Solid Tumor (RECIST version 1.1) criteria, responses 
were assessed and categorized as complete remission 
(CR), partial response (PR), stable disease (SD) or 
progressive disease (PD).
Safety and tolerability
Throughout the study, safety was assessed by 
monitoring and recording AEs, vital signs, clinical 
chemistry, hematology, and urinalysis. Event severity 
was graded according to the National Cancer Institute 
Common Terminology Criteria Adverse Events version 
4.0. Dose modification for gefitinib and nimotuzumab 
was not allowed. Treatment interruption was required for 
grade 3 and 4 toxicities per the protocol algorithm. A cycle 
could be delayed up to 2 weeks to allow sufficient time for 
recovery. If treatment could not be started after 2 weeks, 
the patient was removed from the study.
Statistical analysis
We used the stratified log-rank test for PFS and 
OS. The ORR and other categorical outcomes between 
the two groups were compared using the chi-squared test 
or Fisher’s exact test. Multivariable cox regression was 
performed to adjust for potential confounders such as sex, 
age, and performance status. We assumed that a PFS rate 
at 3 months of 0.55 would indicate clinical usefulness 
of the regimen, whereas a PFS rate at 3 months of 0.4 
would be the lower limit of interest. Assuming 12 months 
for accrual and additional 12 months for follow-up, 71 
patients per arm were needed to achieve 80% power to 
detect a difference of 0.15 in PFS rate at 3 months at a 
two-sided type. Taking drop-out rate into account, the total 
sample size was set at 160 (80 for each treatment arm). 
Efficacy and safety analyses were planned for patients 
who received at least 1 dose of the treatment. PFS and OS 
were analyzed using the Kaplan–Meier method to estimate 
the median values with 95% CIs. Two-sided P-values less 
than 0.1 for the PFS and less than 0.05 for the others were 
considered statistically significant. All statistical analyses 
were performed using SPSS ver. 16.0 for Windows.
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